Candel therapeutics reports first quarter 2025 financial results and recent corporate highlights

Needham, mass., may 13, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the first quarter ended march 31, 2025, and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking